SCHEMBL2863172

SCHEMBL2863172

CC(=O)N(CCCCNCCCNC(=O)c1ccc(O)cc1)CCCn1c(=O)[nH]c2ccccc2c1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.52
HPGD P15428 2/20 0.52
MAPK10 P53779 1/20 0.52
HSD17B10 Q99714 5/20 0.49
GLA P06280 4/20 0.49
MPO P05164 2/20 0.48
GAA P10253 7/20 0.48
KDM4E B2RXH2 5/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 4/20 0.47
TP53 P04637 3/20 0.47
POLB P06746 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 3/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2862784 0.97 LMNA (0.52) LMNAHPGDMAPK10HSD17B10GLA
SCHEMBL2862973 0.95 LMNA (0.55) LMNAHPGDMAPK10HSD17B10GLA
SCHEMBL2864602 0.89 LMNA (0.58) LMNAHPGDMAPK10HSD17B10GLA
SCHEMBL2854670 0.87 MPO (0.63) LMNAHPGDMAPK10HSD17B10GLA
Otaplimastat SCHEMBL30083452 0.87 MPO (0.60) LMNAHPGDMAPK10HSD17B10GLA
Otaplimastat SCHEMBL2858656 0.87 MPO (0.60) LMNAHPGDMAPK10HSD17B10GLA
SCHEMBL17598944 0.87 LMNA (0.48) LMNAHPGDMAPK10HSD17B10GLA
SCHEMBL2864263 0.82 MPO (0.69) HPGDHSD17B10GLAMPOGAA
SCHEMBL2859666 0.81 MPO (0.71) LMNAHPGDMAPK10HSD17B10GLA
SCHEMBL2854663 0.79 MPO (0.67) HPGDHSD17B10GLAMPOGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9290480-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same Shin Poong Pharmaceuticals Co., Ltd. (KR) 2016-03-22 US claimed
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-04-25 US claimed
US-8404696-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-03-26 US claimed
EP-2239257-B1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2012-06-06 EP claimed
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2010-12-09 US claimed
EP-2239257-A2 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME Shin Poong Pharmaceutical Co. Ltd. (KR) 2010-10-13 EP claimed
US-9290480-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same Shin Poong Pharmaceuticals Co., Ltd. (KR) 2016-03-22 US disclosed
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-04-25 US disclosed
US-8404696-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-03-26 US disclosed
EP-2239257-B1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2012-06-06 EP disclosed
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2010-12-09 US disclosed
EP-2239257-A2 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME Shin Poong Pharmaceutical Co. Ltd. (KR) 2010-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME AQP4, PMP22, CNTN1 LMNA 1933/4885HPGD 283/4885MAPK10 1362/4885
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same AQP4, PMP22, CNTN1 LMNA 1933/4885HPGD 283/4885MAPK10 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.